Stock Events

Stock Events

Neuraxis 

$7.50
22
-$0.30-3.85%Monday 04:42

Statistics

Day High
7.5
Day Low
7.5
52W High
9
52W Low
6.69
Volume
12
Avg. Volume
-
Mkt Cap
94.18M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 9Expected
Q3 2025
Q1 2026
Q2 2026
Next
-0.32
-0.27
-0.23
-0.18
Expected EPS
-0.21
Actual EPS
N/A

Financials

-241.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.57MRevenue
-8.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NRXS.BOATS. It's not an investment recommendation.
Nebius Group N.V.
5
NBIS
Bitcoin
4
BTC.CRYPTO
Omada Health
4
OMDA
Meta Platforms
3
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, directly competing in Neuraxis's therapeutic area.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has a strong portfolio in neuroscience, including treatments for conditions that Neuraxis targets.
Novartis
NVS
Mkt Cap303.67B
Novartis offers several neurological products that compete with Neuraxis's treatments.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a diversified neuroscience division that develops drugs for disorders also targeted by Neuraxis.
Merck
MRK
Mkt Cap368.89B
Merck conducts extensive research in neurology, posing competition in overlapping disease areas with Neuraxis.
Rogers
ROG
Mkt Cap2.37B
Roche has significant investments in neurodegenerative and psychiatric disorders, competing with Neuraxis's research focus.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops medications for neurological conditions, similar to Neuraxis.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie has therapies for CNS disorders, directly competing with Neuraxis's product line.
AMGEN
AMGN
Mkt Cap251.94B
Amgen's focus on neuroscience, including Alzheimer's and migraine, places it in direct competition with Neuraxis.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca has a strong neurology segment that competes with Neuraxis in multiple therapeutic areas.

About

Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Show More
CEO
ISIN
US64134X2018

Listings

BOATS
BOATS
NRXS.BOATS
XASE
US
NRXS

0 Comments

Share your thoughts

FAQs

What is Neuraxis stock price today?▼
The current price of NRXS.BOATS is $7.50 USD — it has decreased by -3.85% in the past 24 hours. Watch Neuraxis stock price performance more closely on the chart.
What is Neuraxis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Neuraxis stocks are traded under the ticker NRXS.BOATS.
What is Neuraxis market cap?▼
Today Neuraxis has the market capitalization of 94.18M
When is the next Neuraxis earnings date?▼
Neuraxis is going to release the next earnings report on November 9, 2026.
What were Neuraxis earnings last quarter?▼
NRXS.BOATS earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.32 USD resulting in a +40.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Neuraxis revenue for the last year?▼
Neuraxis revenue for the last year amounts to 3.57M USD.
What is Neuraxis net income for the last year?▼
NRXS.BOATS net income for the last year is -8.62M USD.
In which sector is Neuraxis located?▼
Neuraxis operates in the Other sector.
When did Neuraxis complete a stock split?▼
Neuraxis has not had any recent stock splits.